Mobidiag, Genewave and Amplidiag have signed a definitive agreement to combine the three companies to set up a new company, which will offer integrated, high-multiplex diagnostic tests for infectious diseases.
Headquartered in Helsinki, Finland, the new company Mobidiag integrates Mobidiag's and Amplidiag's high-multiplex proprietary diagnostic test portfolios with Genewave's automated and integrated test platform.
Mobidiag CEO Tuomas Tenkanen said, "The fusion of these three complementary companies creates a unique opportunity to bring forward the next generation of infectious disease diagnostics to dramatically improve global health care."
Genewave's GeneSpress system is an automated and integrated platform for highly multiplexed molecular diagnostic tests and Mobidiag's clinically proven, CE-IVD marked Prove-it diagnostic tests enable up to 84 pathogens and antibiotic resistance markers to be detected in a single assay.
Genewave develops, manufactures and markets microarray instrumentation for diagnostic, clinical and life science research while Amplidiag provides a broad panel of diagnostic tests for infectious diseases.
The global molecular diagnostics market exceeds € 5bn and is growing more than 15% annually, according to Mobidiag.
